Alpha 2.0
Login Register
» Articles » PMID: 33773995

The Evolution of Biologics Administration From Intravenous to Subcutaneous: Treatments for Inflammatory Bowel Disease Go Home

Overview
Journal Gastroenterology
Specialty Gastroenterology
Date 2021 Mar 28
PMID 33773995
Citations 5
Authors
Virginia Solitano
Lucine Vuitton
Laurent Peyrin-Biroulet
Silvio Danese
Affiliations
Soon will be listed here.
Citing Articles

Designing for medication adherence in inflammatory bowel disease: multi-disciplinary approaches for self-administrable biotherapeutics.

Feig V, Zhang S, Patel A, Santos B, Kang Z, Wasan S EClinicalMedicine. 2025; 77:102850.

PMID: 39763512 PMC: 11701474. DOI: 10.1016/j.eclinm.2024.102850.

Toward Patient Centricity: Why Do Patients With Inflammatory Bowel Disease Participate in Pharmaceutical Clinical Trials? A Mixed-Methods Exploration of Study Participants.

Solitano V, Prins H, Archer M, Guizzetti L, Jairath V Crohns Colitis 360. 2024; 6(2):otae019.

PMID: 38595967 PMC: 11003535. DOI: 10.1093/crocol/otae019.

Leveraging Virtual Technology to Conduct Clinical Trials in Inflammatory Bowel Disease.

Noor N, Siegel C Gastroenterol Hepatol (N Y). 2023; 19(8):468-474.

PMID: 37772152 PMC: 10524427.

Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.

Alten R, An Y, Kim D, Yoon S, Peyrin-Biroulet L Clin Drug Investig. 2022; 42(6):477-489.

PMID: 35657560 DOI: 10.1007/s40261-022-01162-6.

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.

Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S Adv Ther. 2022; 39(6):2342-2364.

PMID: 34988877 PMC: 8731678. DOI: 10.1007/s12325-021-01990-6.